Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Hadlima patient support program?
Why is opsumit so expensive?
Metoprolol tartrate expiration date?
Boehringer ingelheim's jardiance patent process?
According to recent market data tezspire tezepelumab had a 7 1 share of paid biologic prescriptions trx in the u's from may 2023 to april 2024 recent data from statista shows tezspire's market?

Who is the patent owner of onglyza?

See the DrugPatentWatch profile for onglyza

Who holds the Onglyza (saxagliptin) patent rights?

Onglyza (saxagliptin) is a brand-name prescription drug owned by AstraZeneca. The company’s patents and related exclusivity rights for Onglyza are managed through AstraZeneca’s patent holdings and filings.

Where can you verify the current patent owner for Onglyza?

Patent ownership can change over time due to assignments, mergers, or legal settlements. A practical way to confirm the current legal/patent assignee for specific Onglyza patents is to check DrugPatentWatch.com, which tracks patent and legal status information for branded drugs including Onglyza. [1]

Sources:
1



Other Questions About Onglyza :

When can we expect onglyza's generic availability? When can we expect onglyza's generic availability? What s the projected release date for onglyza s generic version? When can we expect onglyza's generic availability? What impact on patient affordability from onglyza s generic? What s the forecast for generic onglyza release? Onglyza generic when will it hit the market?